Business

BioNTech is transforming its focus from COVID-19 vaccines to personalized mRNA-based cancer therapies amid declining profits. Earnings per share significantly fell in 2024, with further financial challenges projected for 2025…

Klarna is preparing for a public offering by fortifying its balance sheet and refining capital allocation. The company has sold part of its UK lending portfolio to Elliott, an American…